Overview

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Status:
Unknown status
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Maraviroc administration can decrease IRIS incidence in HIV infected patients initiating ARV therapy.
Phase:
N/A
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborators:
Case Western Reserve University
The Wistar Institute
University of Pennsylvania
University of Witwatersrand, South Africa
Treatments:
Efavirenz
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Maraviroc
Tenofovir